TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04112407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Phototherapy
Description: Phototherapy in the blue light spectrum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzyl Peroxide
Description: Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzyl Peroxide
Description: Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Standard surgical site preparation with no P. acnes pretreatment
Study: NCT04032392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous γδT cells
Description: Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
Study: NCT03482765

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 1
Description: The product under investigation is a unique probiotic.
Study: NCT02582411

Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy
Description: A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated

Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy
Description: A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated

Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy
Description: A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
Study: NCT03482765

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 2
Description: The product under investigation is a unique probiotic.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline Cellulose
Study: NCT02239588

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral consumption
Description: Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral consumption
Description: Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral consumption
Description: Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)
Study: NCT02582411

Intervention type: DEVICE
Intervention: Doppler Optical Coherence Tomography
Description: A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time.
Study: NCT00926939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for the abstinence of smoking
Description: Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for submission of videos with CO sample
Description: This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
Study: NCT03166319

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI, including intracranial vessel wall imaging
Description: MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
Study: NCT01888757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Study: NCT03211325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study: NCT02801929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987518)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - SR15-72_V27-010).
Study: NCT00548964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 600-900mg of Li carbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg of ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5mg/kg of ketamine
Study: NCT00725413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etonogestrel implant (Implanon)
Description: subdermal etonogestrel implant
Study: NCT02681601

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrawell Powder
Description: The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Only
Description: Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OmegaRich fish oil supplement
Description: OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA.
Study: NCT04555421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen
Description: Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
Study: NCT00772304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% / Azelastine 137 mcg
Description: single dose; 2 sprays per nostril
Study: NCT03493178

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glycine
Description: Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: Dietary Supplement: NAC will be supplemented in the active arm for 12-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Dietary Supplement: Alanine will be supplemented in the placebo arm for 12-weeks
Study: NCT04318444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
Study: NCT03758625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a1DC + inactivated whole autologous HIV
Description: Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a1DC + conserved HIV peptides
Description: Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: a1DC + no antigen
Description: Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pgDC + inactivated whole autologous HIV
Description: Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pgDC + conserved HIV peptides
Description: Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pgDC + no antigen
Description: Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
Study: NCT01216410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenylephrine infusion
Description: Prophylactic phenylephrine infusion after spinal and placebo antiemetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Group
Description: Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
Study: NCT01397955

Intervention type: DRUG
Intervention: E2 transdermal (Julina, BAY86-5435)
Description: Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
Study: NCT05550792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optimizer smart
Description: The CCM implantation procedure was performed in the right precordial region of the chest (the right subclavian area). Two active fixation Ingevity leads (Boston Scientific) were advanced via the right subclavian vein into the right ventricle (RV) and actively fixed to the right ventricular septum for ventricular sensing and delivery of CCM signals.
Study: NCT01967901

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care management program
Description: The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care management program
Description: The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care management program
Description: The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care management program
Description: The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
Study: NCT00241358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMD3100

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplant
Study: NCT03114774

Intervention type: DEVICE
Intervention: The bispectral index (BIS) monitoring

Intervention type: BEHAVIORAL
Intervention: Ramsay Sedation Scale (RSS) Score monitoring
Study: NCT02196142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Mannitol
Description: Drug: Placebo Mannitol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Mannitol
Description: Drug: Placebo Mannitol
Study: NCT00968253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
Study: NCT04231123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block with local anesthetic
Description: After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PENG Block with 0,9% saline
Description: After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
Study: NCT00968253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV on Day 4 and Day 11 ± 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV on Day 4 and Day 11 ± 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m\^2 IV continuous infusion daily for 24 hours days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m\^2 IV continuous infusion daily for 24 hours days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
Study: NCT03317873

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testmeal B
Description: The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testmeal B
Description: The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
Study: NCT03131479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
Study: NCT00968253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C (Cytarabine)
Description: 3 gm/m\^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C (Cytarabine)
Description: 3 gm/m\^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
Study: NCT00365222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 75 mg/m2 /d
Study: NCT03805425

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PiXL
Description: The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.
Study: NCT04032652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal dialysis
Description: Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal dialysis
Description: Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal dialysis
Description: Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal dialysis
Description: Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
Study: NCT01703325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% triamcinolone , 0.05% clobetasol propionate ointment
Description: Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~* Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~* Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~* Group C: Controlled group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% triamcinolone , 0.05% clobetasol propionate ointment
Description: Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~* Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~* Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~* Group C: Controlled group
Study: NCT01120535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inferior Vena Cava Filter
Description: Inplant of filter in inferior vena cava.